Duration of response of lisdexamfetamine dimesylate in children and adolescents with ADHD
Alessandro Zuddas(University of Cagliari), Liza Squires, Michel Lecendreux(Laboratoire National de Référence), Regina Dittmann(Forschungszentrum Jülich), Nicholas Higgins(Takeda (United States)), Ralph Bloomfield(AstraZeneca (United Kingdom)), Richard Civil(Takeda (United States)), Isabel Hernández Otero(Victoria School of Management), Colleen Anderson(Takeda (United States)), Tobias Banaschewski(Heidelberg University)
Cited by 1
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
|Cell|2019|1.5k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Attention-deficit/hyperactivity disorder
|Nature Reviews Disease Primers|2015|1.3k